Cancer BiologybioRxiv
CRCM5484: A BET- BDII Selective Compound With Differential Anti-Leukemic Drug Modulation
K. Carrasco, C. Montersino, C. Derviaux…·S. Betzi
The paper identifies CRCM5484, a BDII-selective BET inhibitor, and shows its differential modulation of anti-leukemic drug activity in combination with other compounds.
DOI 10.1021/acs.jmedchem.1c02168